Harmen Mons

Title: Harmen Mons: Innovator in (Thio)morpholine Derivatives

Introduction

Harmen Mons is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly through his work on (thio)morpholine derivatives. With a total of 2 patents, his innovations are aimed at addressing S1P receptor-mediated diseases.

Latest Patents

Mons' latest patents focus on (thio)morpholine derivatives as S1P modulators. The present disclosure relates to these derivatives, which are defined by a specific formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof. Importantly, the derivatives of formula (I) are not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile. The compounds developed in this invention exhibit affinity to S1P receptors and may be utilized in the treatment, alleviation, or prevention of diseases and conditions mediated by these receptors.

Career Highlights

Harmen Mons is currently associated with AbbVie Bahamas Limited, where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential therapeutic applications.

Collaborations

Mons collaborates with esteemed colleagues such as Wouter I Iwema Bakker and Hein K A C Coolen, contributing to a dynamic research environment.

Conclusion

Harmen Mons stands out as an influential inventor in the realm of pharmaceutical innovations, particularly with his work on (thio)morpholine derivatives. His contributions have the potential to significantly impact the treatment of various diseases.